File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Novel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction

TitleNovel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction
Authors
KeywordsInflammation
mast cell activation
non-IgE–mediated allergies
skin
structure aided drug designing
Issue Date5-Apr-2023
PublisherElsevier
Citation
Journal of Allergy and Clinical Immunology, 2023, v. 151, n. 4, p. 1110-1122 How to Cite?
Abstract

Background: Activation of Mas-related G protein-coupled receptor X2 (MRGPRX2) is a crucial non-IgE pathway for mast cell activation associated with allergic reactions and inflammation. Only a few peptides and small compounds targeting MRGPRX2 have been reported, with limited information on their pharmacologic activity.

Objective: We sought to develop novel small molecule MRGPRX2 antagonists to treat MRGPRX2-mediated allergies and inflammation.

Methods: A computational approach was used to design novel small molecules as MRGPRX2 antagonists. The short-listed molecules were synthesized and characterized by liquid chromatography and mass spectrometry as well as nuclear magnetic resonance. Inhibitory activity on MRGPRX2 signaling was assessed in vitro by using functional bioassays (b-hexosaminidase, calcium flux, and chemokine synthesis) and receptor activation assays (b-arrestin recruitment and Western blot analysis) in human LAD-2 mast cells and HTLA cells. In vivo effects of the novel MRGPRX2 antagonists were assessed using a mouse model of acute allergy and systemic anaphylaxis.

Results: The novel small molecules demonstrated higher binding affinity with MRGPRX2 in the docking study. The half -maximal inhibitory concentration is in the low micromolar range (5-21 mM). The small molecules inhibited not only the early phase of mast cell activation but also the late phase, associated with chemokine and prostaglandin release. Further, Western blot analysis revealed inhibition of downstream phospholipase C -g, extracellular signal-regulated protein kinase 1/2, and Akt signaling pathway. Moreover, in the mouse models of allergies, small molecule administration effectively blocks acute, systemic allergic reactions and inflammation and prevents systemic anaphylaxis.

Conclusion: The small molecules might hold a significant therapeutic promise to treat MRGPRX2-mediated allergies and inflammation.


Persistent Identifierhttp://hdl.handle.net/10722/329223
ISSN
2023 Impact Factor: 11.4
2023 SCImago Journal Rankings: 3.701
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKumar, M-
dc.contributor.authorDuraisamy, K-
dc.contributor.authorAnnapureddy, RR-
dc.contributor.authorChan, CB-
dc.contributor.authorChow, BKC-
dc.date.accessioned2023-08-05T07:56:14Z-
dc.date.available2023-08-05T07:56:14Z-
dc.date.issued2023-04-05-
dc.identifier.citationJournal of Allergy and Clinical Immunology, 2023, v. 151, n. 4, p. 1110-1122-
dc.identifier.issn0091-6749-
dc.identifier.urihttp://hdl.handle.net/10722/329223-
dc.description.abstract<p>Background: Activation of Mas-related G protein-coupled receptor X2 (MRGPRX2) is a crucial non-IgE pathway for mast cell activation associated with allergic reactions and inflammation. Only a few peptides and small compounds targeting MRGPRX2 have been reported, with limited information on their pharmacologic activity. <br></p><p>Objective: We sought to develop novel small molecule MRGPRX2 antagonists to treat MRGPRX2-mediated allergies and inflammation.<br></p><p>Methods: A computational approach was used to design novel small molecules as MRGPRX2 antagonists. The short-listed molecules were synthesized and characterized by liquid chromatography and mass spectrometry as well as nuclear magnetic resonance. Inhibitory activity on MRGPRX2 signaling was assessed in vitro by using functional bioassays (b-hexosaminidase, calcium flux, and chemokine synthesis) and receptor activation assays (b-arrestin recruitment and Western blot analysis) in human LAD-2 mast cells and HTLA cells. In vivo effects of the novel MRGPRX2 antagonists were assessed using a mouse model of acute allergy and systemic anaphylaxis.<br></p><p>Results: The novel small molecules demonstrated higher binding affinity with MRGPRX2 in the docking study. The half -maximal inhibitory concentration is in the low micromolar range (5-21 mM). The small molecules inhibited not only the early phase of mast cell activation but also the late phase, associated with chemokine and prostaglandin release. Further, Western blot analysis revealed inhibition of downstream phospholipase C -g, extracellular signal-regulated protein kinase 1/2, and Akt signaling pathway. Moreover, in the mouse models of allergies, small molecule administration effectively blocks acute, systemic allergic reactions and inflammation and prevents systemic anaphylaxis.<br></p><p>Conclusion: The small molecules might hold a significant therapeutic promise to treat MRGPRX2-mediated allergies and inflammation.</p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofJournal of Allergy and Clinical Immunology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectInflammation-
dc.subjectmast cell activation-
dc.subjectnon-IgE–mediated allergies-
dc.subjectskin-
dc.subjectstructure aided drug designing-
dc.titleNovel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction-
dc.typeArticle-
dc.identifier.doi10.1016/j.jaci.2022.12.805-
dc.identifier.pmid36581009-
dc.identifier.scopuseid_2-s2.0-85146715958-
dc.identifier.volume151-
dc.identifier.issue4-
dc.identifier.spage1110-
dc.identifier.epage1122-
dc.identifier.isiWOS:000982186000001-
dc.publisher.placeNEW YORK-
dc.identifier.issnl0091-6749-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats